Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Amicus Therapeutics (FOLD) over the last 17 years, with Q3 2025 value amounting to $73.3 million.

  • Amicus Therapeutics' Short-term Investments rose 35493.48% to $73.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.3 million, marking a year-over-year increase of 35493.48%. This contributed to the annual value of $36.2 million for FY2024, which is 768.25% down from last year.
  • Amicus Therapeutics' Short-term Investments amounted to $73.3 million in Q3 2025, which was up 35493.48% from $72.3 million recorded in Q2 2025.
  • Amicus Therapeutics' 5-year Short-term Investments high stood at $237.3 million for Q4 2021, and its period low was $16.1 million during Q3 2024.
  • Moreover, its 5-year median value for Short-term Investments was $73.3 million (2025), whereas its average is $103.3 million.
  • Per our database at Business Quant, Amicus Therapeutics' Short-term Investments crashed by 7797.89% in 2023 and then skyrocketed by 35493.48% in 2025.
  • Amicus Therapeutics' Short-term Investments (Quarter) stood at $237.3 million in 2021, then tumbled by 38.99% to $144.8 million in 2022, then crashed by 72.92% to $39.2 million in 2023, then dropped by 7.68% to $36.2 million in 2024, then soared by 102.49% to $73.3 million in 2025.
  • Its last three reported values are $73.3 million in Q3 2025, $72.3 million for Q2 2025, and $68.9 million during Q1 2025.